07:06 AM EST, 02/03/2025 (MT Newswires) -- Pfizer ( PFE ) said Monday its phase 3 study of Braftovi combination regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with a type of metastatic colorectal cancer.

The company said Braftovi, in combination with cetuximab and mFOLFOX6, also showed a significant improvement in overall survival compared to patients receiving standard chemotherapy, with or without bevacizumab, a key secondary endpoint in the trial.

The drugmaker said it plans to share the results with the US Food and Drug Administration to potentially support full approval of the Braftovi combination regimen in patients.